Cytokinetics Inc (NASDAQ:CYTK) Could Actually Go To 67 In 12 Months

In last trading session, Cytokinetics Inc (NASDAQ:CYTK) saw 0.77 million shares changing hands with its beta currently measuring 0.59. Company’s recent per share price level of $32.30 trading at $0.22 or 0.69% at ring of the bell on the day assigns it a market valuation of $3.86B. That closing price of CYTK’s stock is at a discount of -90.03% from its 52-week high price of $61.38 and is indicating a premium of 9.26% from its 52-week low price of $29.31.

For Cytokinetics Inc (CYTK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.36. Splitting up the data highlights that, out of 12 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 11 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Cytokinetics Inc (NASDAQ:CYTK) trade information

Cytokinetics Inc’s shares saw a change of -31.34% in year-to-date performance and have moved 4.13% in past 5-day. Cytokinetics Inc (NASDAQ:CYTK) showed a performance of -2.24% in past 30-days.

Wall Street analysts have assigned a consensus price target of 61 to the stock, which implies a rise of 47.05% to its current value. Analysts have been projecting 55 as a low price target for the stock while placing it at a high target of 67. It follows that stock’s current price would drop -70.28% in reaching the projected high whereas dropping to the targeted low would mean a loss of -70.28% for stock’s current value.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -20.02% during past 5 years. In 2025, company’s earnings growth rate is likely to be around -8.77% while estimates for its earnings growth in next 5 years are of 15.83%.

Cytokinetics Inc (NASDAQ:CYTK)’s Major holders

BLACKROCK INC. is the top institutional holder at CYTK for having 14.67 million shares of worth $794.97 million. And as of 2024-06-30, it was holding 13.4317 of the company’s outstanding shares.

The second largest institutional holder is FMR LLC, which was holding about 11.52 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.5485 of outstanding shares, having a total worth of $624.32 million.

On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and iShares Trust-iShares Core S&P Mid-Cap ETF are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 4.07 shares of worth $131.39 million or 3.41% of the total outstanding shares. The later fund manager was in possession of 3.82 shares on Apr 30, 2025 , making its stake of worth around $123.42 million in the company or a holder of 3.20% of company’s stock.

Marketing Sentinel
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.